STIMOXYGEN LTD
Company No. NI677236
Information for Filing with The Registrar
31 March 2024
STIMOXYGEN LTD

Directors Report Registrar
The Directors present their report and the accounts for the year ended 31 March 2024.
Principal activities
The principal activity of the company during the year under review was . Research & experimental development on biotechnology & Manufacture of medical & dental instruments & supplies
Directors
The Directors who served at any time during the year were as follows:
A.McHale
F.Begley
J.Callan
L.Russell
S.Farrell
The above report has been prepared in accordance with the provisions applicable to companies subject to the small companies regime as set out in Part 15 of the Companies Act 2006.
Signed on behalf of the board
S.Farrell
Director
31 March 2024
STIMOXYGEN LTD

Balance Sheet Registrar
at31 March 2024
Company No.NI677236Notes20242023
££
Fixed assets
Intangible assets41,5402,090
Tangible assets51,5742,263
3,1144,353
Current assets
Debtors61,35925,277
Cash at bank and in hand66,003113,517
67,362138,794
Creditors: Amount falling due within one year7
(635)
(158,870)
Net current assets/(liabilities)66,727
(20,076)
Total assets less current liabilities69,841
(15,723)
Creditors: Amounts falling due after more than one year8
(166,130)
-
Net liabilities
(96,289)
(15,723)
Capital and reserves
Called up share capital1010
Share premium account-20,44717,131
Profit and loss account-
(116,746)
(32,864)
Total equity
(96,289)
(15,723)
These accounts have been prepared in accordance with the special provisions applicable to companies subject to the small companies regime of the Companies Act 2006.
For the year ended 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
As permitted by section 444 (5A)of the Companies Act 2006 the directors have not delivered to the Registrar a copy of the company's profit and loss account.
Approved by the board on 31 March 2024 and signed on its behalf by:
S.Farrell
Director
31 March 2024
STIMOXYGEN LTD

Notes to the Accounts Registrar
for the year ended 31 March 2024
1General information
STIMOXYGEN LTD is a private company limited by shares and incorporated in Northern Ireland.
Its registered number is: NI677236
Its registered office is:
Victoria house
Gloucester street
BELFAST
BT1 4LS
The accounts have been prepared in accordance with FRS 102 Section 1A - The Financial Reporting Standard applicable in the UK and Republic of Ireland and the Companies Act 2006.
2Accounting policies
Turnover
Turnover is measured at the fair value of the consideration received or receivable. Turnover is reduced for estimated customer returns, rebates and other similar allowances. Revenue from the sale of goods is recognised when all the following conditions are satisfied: • the Company has transferred to the buyer the significant risks and rewards of ownership of the goods; • the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold; • the amount of revenue can be measured reliably; • it is probable that the economic benefits associated with the transaction will flow to the Company; and • the costs incurred or to be incurred in respect of the transaction can be measured reliably. Specifically, revenue from the sale of goods is recognised when goods are delivered and legal title is passed.
Intangible fixed assets
Intangible fixed assets are carried at cost less accumulated amortisation and impairment losses.
Tangible fixed assets and depreciation
Tangible fixed assets held for the company's own use are stated at cost less accumulated depreciation and accumulated impairment losses. At each balance sheet date, the company reviews the carrying amount of its tangible fixed assets to determine whether there is any indication that any items have suffered an impairment loss. If any such indication exists, the recoverable amount of an asset is estimated in order to determine the extent of the impairment loss.
Depreciation is provided at the following annual rates in order to write off the cost or valuation less the estimated residual value of each asset over its estimated useful life:
Research and development costs
Expenditure on research and development is written off in the year it is incurred unless it meets the criteria to allow it to be capitalised. Costs of research are always written off in the year in which they are incurred. Where development costs are recognised as an asset, they are amortised over the period expected to benefit from them. Amortisation of the capitalised costs begins once the developed product comes into use, typically at rate of 33.33% straight line.
Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax. The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the profit and loss account because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Deferred tax assets are generally recognised for all deductible timing differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Current or deferred tax for the year is recognised in profit or loss, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
Trade and other debtors
Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method, less impairment losses for bad and doubtful debts.
Trade and other creditors
Short term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.
3Employees
20242023
NumberNumber
The average monthly number of employees (including directors) during the year was:23
4Intangible fixed assets
GoodwillPatents and trade-marksDevelopment costsOtherTotal
£££££
Cost
At 1 April 2023-2,750--2,750
At 31 March 2024-2,750--2,750
Amortisation and impairment
At 1 April 2023-660--660
Charge for the year-550--550
At 31 March 2024-1,210--1,210
Net book values
At 31 March 2024-1,540--1,540
At 31 March 2023-2,090--2,090
5Tangible fixed assets
Land and buildingsPlant and machineryMotor vehiclesFixtures, fittings and equipmentTotal
£££££
Cost or revaluation
At 1 April 2023-2,230-7282,958
At 31 March 2024-2,230-7282,958
Depreciation
At 1 April 2023-372-323695
Charge for the year-446-243689
At 31 March 2024-818-5661,384
Net book values
At 31 March 2024-1,412-1621,574
At 31 March 2023-1,858-4052,263
6Debtors
20242023
££
Corporation tax recoverable35311,496
VAT recoverable5022,584
Other debtors10-
Prepayments and accrued income49411,197
1,35925,277
7Creditors:
amounts falling due within one year
20242023
££
Trade creditors-1,442
Taxes and social security-3,086
Loans from directors43-
Other creditors292154,342
Accruals and deferred income300-
635158,870
8Creditors:
amounts falling due after more than one year
20242023
££
Other loans166,130-
166,130-
STIMOXYGEN LTDNI67723631 March 202401 April 2023false31 March 2024BTCSoftware AP Solution 2022 9.4.039.4.03NI6772362023-04-012024-03-31NI6772362024-03-31NI677236bus:Director12023-04-012024-03-31NI677236bus:Director22023-04-012024-03-31NI677236bus:Director32023-04-012024-03-31NI677236bus:Director42023-04-012024-03-31NI677236bus:Director52023-04-012024-03-31NI6772362023-03-31NI677236core:WithinOneYear2024-03-31NI677236core:WithinOneYear2023-03-31NI677236core:AfterOneYear2024-03-31NI677236core:AfterOneYear2023-03-31NI677236core:ShareCapital2024-03-31NI677236core:ShareCapital2023-03-31NI677236core:SharePremium2024-03-31NI677236core:SharePremium2023-03-31NI677236core:RetainedEarningsAccumulatedLosses2024-03-31NI677236core:RetainedEarningsAccumulatedLosses2023-03-31NI677236countries:UnitedKingdom2023-04-012024-03-31NI677236bus:RegisteredOffice2023-04-012024-03-31NI6772362022-04-012023-03-31NI677236core:Goodwill2023-04-01NI677236core:PatentsTrademarksLicencesConcessionsSimilar2023-04-01NI677236core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-04-01NI677236core:OtherResidualIntangibleAssets2023-04-01NI6772362023-04-01NI677236core:Goodwill2024-03-31NI677236core:PatentsTrademarksLicencesConcessionsSimilar2024-03-31NI677236core:DevelopmentCostsCapitalisedDevelopmentExpenditure2024-03-31NI677236core:OtherResidualIntangibleAssets2024-03-31NI677236core:Goodwill2023-04-012024-03-31NI677236core:PatentsTrademarksLicencesConcessionsSimilar2023-04-012024-03-31NI677236core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-04-012024-03-31NI677236core:OtherResidualIntangibleAssets2023-04-012024-03-31NI677236core:Goodwill2023-03-31NI677236core:PatentsTrademarksLicencesConcessionsSimilar2023-03-31NI677236core:DevelopmentCostsCapitalisedDevelopmentExpenditure2023-03-31NI677236core:OtherResidualIntangibleAssets2023-03-31NI677236core:LandBuildings2023-04-01NI677236core:PlantMachinery2023-04-01NI677236core:MotorVehicles2023-04-01NI677236core:FurnitureFittingsToolsEquipment2023-04-01NI677236core:LandBuildings2024-03-31NI677236core:PlantMachinery2024-03-31NI677236core:MotorVehicles2024-03-31NI677236core:FurnitureFittingsToolsEquipment2024-03-31NI677236core:LandBuildings2023-04-012024-03-31NI677236core:PlantMachinery2023-04-012024-03-31NI677236core:MotorVehicles2023-04-012024-03-31NI677236core:FurnitureFittingsToolsEquipment2023-04-012024-03-31NI677236core:LandBuildings2023-03-31NI677236core:PlantMachinery2023-03-31NI677236core:MotorVehicles2023-03-31NI677236core:FurnitureFittingsToolsEquipment2023-03-31NI677236bus:SmallEntities2023-04-012024-03-31NI677236bus:FullAccounts2023-04-012024-03-31NI677236bus:AuditExempt-NoAccountantsReport2023-04-012024-03-31NI677236bus:PrivateLimitedCompanyLtd2023-04-012024-03-31iso4217:GBPxbrli:pure